Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Radiofrequency, laser, and adhesive ablation of the saphenous veins; office and vein-clinic heavy. Main billing specialties: vascular surgery and interventional radiology.
Medicare fee-for-service superficial venous ablation cases in the 47 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (235 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 243 | 23,074−4.3%/yr | −4.3%/yr | 9.82.0× | 100% | 26,100 in 2030+2.1%/yr |
| Texas | 220 | 22,416+0.2%/yr | +0.2%/yr | 9.92.0× | 98% | 30,300 in 2030+5.1%/yr |
| California | 224 | 22,010−1.1%/yr | −1.1%/yr | 6.31.2× | 98% | 24,700 in 2030+2%/yr |
| Arizona | 94 | 10,087−0.8%/yr | −0.8%/yr | 13.02.6× | 100% | 10,200 in 2030+0.2%/yr |
| New York | 132 | 8,630−5.2%/yr | −5.2%/yr | 4.50.9× | 97% | 9,880 in 2030+2.3%/yr |
| Illinois | 97 | 8,273−2.9%/yr | −2.9%/yr | 5.81.1× | 94% | 9,750 in 2030+2.8%/yr |
| Tennessee | 54 | 5,388+1.6%/yr | +1.6%/yr | 7.31.5× | 100% | 5,500 in 2030+0.4%/yr |
| New Jersey | 70 | 4,906−2.3%/yr | −2.3%/yr | 4.50.9× | 97% | 6,260 in 2030+4.1%/yr |
| Georgia | 64 | 4,583−7.7%/yr | −7.7%/yr | 5.01.0× | 100% | 5,820 in 2030+4.1%/yr |
| North Carolina | 57 | 4,216−3.9%/yr | −3.9%/yr | 4.00.8× | 97% | 3,890 in 2030−1.3%/yr |
| Maryland | 43 | 3,848−12%/yr | −12%/yr | 4.30.8× | 100% | 3,720 in 2030−0.6%/yr |
| Virginia | 57 | 3,844−3.8%/yr | −3.8%/yr | 3.50.7× | 94% | 4,330 in 2030+2%/yr |
| Colorado | 41 | 3,790+0.3%/yr | +0.3%/yr | 7.41.5× | 99% | 5,330 in 2030+5.9%/yr |
| Ohio | 47 | 3,475−3.2%/yr | −3.2%/yr | 3.00.6× | 79% | 4,520 in 2030+4.5%/yr |
| Pennsylvania | 45 | 3,315−8.9%/yr | −8.9%/yr | 2.30.5× | 87% | 3,220 in 2030−0.5%/yr |
| Michigan | 44 | 2,935−15%/yr | −15%/yr | 3.30.7× | 95% | 2,850 in 2030−0.5%/yr |
| Missouri | 28 | 2,393−9.5%/yr | −9.5%/yr | 3.70.7× | 75% | 2,400 in 2030+0.1%/yr |
| Connecticut | 39 | 2,246−8.9%/yr | −8.9%/yr | 6.41.3× | 100% | 2,440 in 2030+1.4%/yr |
| Indiana | 29 | 2,244−3.2%/yr | −3.2%/yr | 3.00.6× | 86% | 2,540 in 2030+2.1%/yr |
| Nevada | 19 | 2,060−8.7%/yr | −8.7%/yr | 6.81.4× | 99% | 2,270 in 2030+1.7%/yr |
| Alabama | 29 | 2,003−5.2%/yr | −5.2%/yr | 4.30.9× | 85% | 2,070 in 2030+0.6%/yr |
| Louisiana | 25 | 1,654−4.9%/yr | −4.9%/yr | 3.80.8× | 99% | 1,580 in 2030−0.8%/yr |
| Massachusetts | 31 | 1,623−5%/yr | −5%/yr | 1.70.3× | 94% | 1,600 in 2030−0.3%/yr |
| South Carolina | 27 | 1,612−7.3%/yr | −7.3%/yr | 2.30.4× | 96% | 1,950 in 2030+3.2%/yr |
| Mississippi | 14 | 1,432−1.3%/yr | −1.3%/yr | 3.70.7× | 88% | 1,870 in 2030+4.6%/yr |
| Wisconsin | 10 | 1,300−2.6%/yr | −2.6%/yr | 2.20.4× | 73% | 1,100 in 2030−2.8%/yr |
| Iowa | 16 | 1,064−7.3%/yr | −7.3%/yr | 2.30.5× | 98% | 970 in 2030−1.5%/yr |
| Oklahoma | 15 | 1,005−11%/yr | −11%/yr | 2.00.4× | 28% | 1,140 in 2030+2.2%/yr |
| Kentucky | 10 | 988−4.4%/yr | −4.4%/yr | 2.00.4× | 83% | 1,300 in 2030+4.7%/yr |
| Minnesota | 14 | 975−3.2%/yr | −3.2%/yr | 2.00.4× | 88% | 1,710 in 2030+9.8%/yr |
| Utah | 15 | 962−9.3%/yr | −9.3%/yr | 4.20.8× | 92% | 750 in 2030−4%/yr |
| Oregon | 18 | 938−1%/yr | −1%/yr | 2.10.4× | 96% | 960 in 2030+0.4%/yr |
| New Mexico | 8 | 925−4.6%/yr | −4.6%/yr | 3.80.8× | 96% | 850 in 2030−1.4%/yr |
| Washington | 7 | 779−7.1%/yr | −7.1%/yr | 1.00.2× | 83% | 860 in 2030+1.7%/yr |
| Kansas | 15 | 766−21%/yr | −21%/yr | 1.80.4× | 38% | 870 in 2030+2.2%/yr |
| South Dakota | 12 | 721+12%/yr | +12%/yr | 5.41.1× | 92% | 1,130 in 2030+7.8%/yr |
| Arkansas | 11 | 666−14%/yr | −14%/yr | 1.70.3× | 78% | 580 in 2030−2.1%/yr |
| Montana | 6 | 568−13%/yr | −13%/yr | 2.90.6× | 94% | 490 in 2030−2.4%/yr |
| Nebraska | 10 | 562−6.2%/yr | −6.2%/yr | 2.10.4× | 70% | 590 in 2030+0.9%/yr |
| Hawaii | 4 | 442+29%/yr | +29%/yr | 3.30.7× | 100% | 390 in 2030−2.2%/yr |
| Wyoming | 4 | 425−3.4%/yr | −3.4%/yr | 3.80.8× | 100% | 570 in 2030+4.9%/yr |
| West Virginia | 6 | 374−9.4%/yr | −9.4%/yr | 1.70.3× | 83% | 400 in 2030+1%/yr |
| Rhode Island | 5 | 302−2.7%/yr | −2.7%/yr | 3.10.6× | 100% | 410 in 2030+5.3%/yr |
| Idaho | 7 | 286−4.7%/yr | −4.7%/yr | 1.30.3× | 72% | 300 in 2030+1.1%/yr |
| Delaware | 7 | 284−5.2%/yr | −5.2%/yr | 1.60.3× | 100% | 440 in 2030+7.4%/yr |
| District of Columbia | 4 | 217−11%/yr | −11%/yr | 3.30.7× | 100% | 270 in 2030+3.5%/yr |
| Maine | 3 | 188−9.3%/yr | −9.3%/yr | 1.10.2× | 100% | 430 in 2030+15%/yr |
Professional codes (what the surgeon bills): CPT 36475, 36478, 36482.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 42 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 1 company. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 42 |
Product codes: PJQ (agent, occluding, vascular, permanent). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 25% of the cases CMS names in Florida; 102 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Peripheral arterial intervention | 1,321 | 182,726−5.9%/yr | −5.9%/yr | 215,300 in 2030+2.8%/yr |
| Dialysis access | 1,721 | 161,268−13%/yr | −13%/yr | 158,700 in 2030−0.3%/yr |
| Thrombectomy, IVC filters & venous stents | 389 | 47,332+0.1%/yr | +0.1%/yr | 62,700 in 2030+4.8%/yr |
| Carotid revascularization | 741 | 36,694−5%/yr | −5%/yr | 40,000 in 2030+1.5%/yr |
| Aortic endografts (EVAR/TEVAR) | 89 | 13,204−6.8%/yr | −6.8%/yr | 13,800 in 2030+0.7%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 5 companies reported engagement with surgeons in the covered states worth $933K in consulting, speaking, meals and travel tied to these products, about $471 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.